Galmed Pharmaceuticals
GLMD
37 hedge funds and large institutions have $52.2M invested in Galmed Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 5 closing their positions.
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
23% more funds holding
Funds holding: 30 → 37 (+7)
0% more ownership
Funds ownership: 0.03% → 0.03% (+0%)
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
31% less call options, than puts
Call options by funds: $87K | Put options by funds: $126K
50% less capital invested
Capital invested by funds: $103M → $52.2M (-$51.2M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FMBTD
First Midwest Bank Trust Division
Joliet,
Illinois
|
+$1.84M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
+$1.17M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$1.15M |
| 4 |
II
Ibex Investors
Denver,
Colorado
|
+$796K |
| 5 |
SIM
Spark Investment Management
New York
|
+$727K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$3M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.56M |
| 3 |
Morgan Stanley
New York
|
-$1.1M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$1.05M |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$599K |
GLMD Hedge Fund Activity: Q4 2018 in Review
37 of the 4,504 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q4 2018, worth a combined $52.2M — down 50% from $103M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new GLMD positions and 5 closed out — a net gain of 7 holders — while 8 added to existing stakes and 8 trimmed.
The largest buyer was First Midwest Bank Trust Division, adding an estimated $1.84M. The largest seller was Millennium Management, cutting an estimated $3M.
- 37 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q4 2018, up from 30 in Q3 2018.
- Funds reported $52.2M of Galmed Pharmaceuticals stock for Q4 2018, down 50% quarter-over-quarter.
- 12 funds opened new Galmed Pharmaceuticals positions in Q4 2018 and 5 closed out, a net change of +7 holders.
- The largest Galmed Pharmaceuticals buyer in Q4 2018 was First Midwest Bank Trust Division, an estimated $1.84M added.
- The largest Galmed Pharmaceuticals seller in Q4 2018 was Millennium Management, an estimated $3M sold.
Based on aggregated 13F filings for Q4 2018.